Virtual magnetic resonance linear accelerator improved adaptive pelvic lymph node radiotherapy dosimetry
Daily magnetic resonance-informed adaptation increased target coverage by 14% and reduced bowel dose by 7% for pelvic lymph node metastases.
Daily magnetic resonance-informed adaptation increased target coverage by 14% and reduced bowel dose by 7% for pelvic lymph node metastases.
Scanned and scattered clinical proton beams produced similar Ewing sarcoma cell survival despite higher oxidative stress signals after scanned delivery.
Diagnostic computed tomography-based single-fraction radiotherapy was feasible for selected non-spine palliative metastases, with no grade 3 or higher acute toxicity.
Three-year locoregional recurrence-free survival was 90.8%, with most locoregional recurrences occurring within or near the radiation field.
All patients receiving more than 8 Gy mean dose or 16 Gy maximum dose to the least exposed ovary developed premature ovarian insufficiency.
Aperture-enhanced proton stereotactic radiosurgery reduced normal brain dose compared with photon plans in most cerebral arteriovenous malformation cases.
A case report linked high-dose Boswellia serrata use for radiation necrosis with reversible acute kidney injury.
A thick gas electron multiplier air chamber showed strong dose linearity under conventional and ultra-high dose rate conditions.
Existing thyroid complication models showed moderate performance and frequent miscalibration in long-term head and neck cancer survivorship.
No radiation myelopathy was observed after target-prioritized intensity modulated radiotherapy for selected nasopharyngeal carcinoma near the spinal cord.
Larger bladder volume was strongly associated with lower planned bladder dose in a static five-fraction prostate radiotherapy analysis.
In free-breathing lung stereotactic ablative radiotherapy, posterior drift exceeded the 4-millimetre margin in 15.7% of patients within 20 minutes.
After stereotactic body radiation therapy for hepatocellular carcinoma, magnetic resonance response evolved over months, making early enhancement alone unreliable.
Synthetic stopping power maps showed small target dose differences, but residual range and low-dose gamma errors still require further validation.
Synthetic computed tomography from cone-beam computed tomography achieved a 98.7% gamma pass rate for head-and-neck dose recalculation.